ATE405272T1 - Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin - Google Patents
Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterinInfo
- Publication number
- ATE405272T1 ATE405272T1 AT05756183T AT05756183T ATE405272T1 AT E405272 T1 ATE405272 T1 AT E405272T1 AT 05756183 T AT05756183 T AT 05756183T AT 05756183 T AT05756183 T AT 05756183T AT E405272 T1 ATE405272 T1 AT E405272T1
- Authority
- AT
- Austria
- Prior art keywords
- cell lymphoma
- deazaaminopterin
- propargyl
- treatment
- amount
- Prior art date
Links
- 206010042971 T-cell lymphoma Diseases 0.000 title abstract 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 title abstract 4
- OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000003442 weekly effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52159304P | 2004-05-30 | 2004-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE405272T1 true ATE405272T1 (de) | 2008-09-15 |
Family
ID=34971703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05756183T ATE405272T1 (de) | 2004-05-30 | 2005-05-31 | Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US7622470B2 (de) |
| EP (1) | EP1750716B1 (de) |
| JP (1) | JP5005532B2 (de) |
| KR (1) | KR101189693B1 (de) |
| CN (2) | CN102824346B (de) |
| AT (1) | ATE405272T1 (de) |
| AU (1) | AU2005249516B2 (de) |
| BR (1) | BRPI0510895A (de) |
| CA (1) | CA2565968C (de) |
| DE (1) | DE602005009176D1 (de) |
| DK (1) | DK1750716T3 (de) |
| ES (1) | ES2313365T3 (de) |
| HR (1) | HRP20080569T3 (de) |
| ME (1) | ME01087B (de) |
| MX (1) | MXPA06013559A (de) |
| NO (1) | NO337276B1 (de) |
| NZ (2) | NZ576849A (de) |
| PL (1) | PL1750716T3 (de) |
| PT (1) | PT1750716E (de) |
| RS (1) | RS50622B (de) |
| SI (1) | SI1750716T1 (de) |
| WO (2) | WO2005117891A1 (de) |
| ZA (1) | ZA200609266B (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| ATE405272T1 (de) | 2004-05-30 | 2008-09-15 | Sloan Kettering Inst Cancer | Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin |
| US8263354B2 (en) | 2004-05-30 | 2012-09-11 | Sloan-Kettering Institute For Cancer Research | Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin |
| US20080188479A1 (en) | 2004-05-30 | 2008-08-07 | Sloan-Kettering Institute For Cancer Research | Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin |
| WO2009018478A2 (en) | 2007-07-31 | 2009-02-05 | Accera, Inc. | Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function |
| WO2009026234A1 (en) * | 2007-08-17 | 2009-02-26 | Allos Therapeutics, Inc. | Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer |
| US20100248249A1 (en) * | 2007-08-17 | 2010-09-30 | Allos Therapeutics, Inc. | Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels |
| US9901578B2 (en) | 2007-08-17 | 2018-02-27 | Allos Therapeutics, Inc. | Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer |
| US9125881B2 (en) | 2008-07-03 | 2015-09-08 | Accera, Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
| WO2010022277A2 (en) * | 2008-08-20 | 2010-02-25 | O'connor Owen A | Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers |
| AU2010345065B2 (en) * | 2010-02-02 | 2014-06-05 | Allos Therapeutics, Inc. | Optically pure diastereomers of 10-propargyl-10-deazaaminopterin and methods of using same |
| CN102984940B (zh) * | 2010-06-02 | 2016-01-13 | 阿罗斯治疗公司 | 用10-炔丙基-10-去氮杂氨基蝶呤治疗甲氨蝶呤抗性病症的方法 |
| AU2011289638B2 (en) * | 2010-08-10 | 2014-10-30 | Allos Therapeutics, Inc. | Methods for extending progression-free survival using 10-propargyl-10-deazaaminopterin |
| WO2013164856A1 (en) | 2012-05-04 | 2013-11-07 | Avra Laboratories Private Limited | A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof |
| CN103274943B (zh) * | 2013-05-24 | 2015-01-21 | 苏州明锐医药科技有限公司 | 4-[1-(2-丙炔基)-3,4-二氧代正丁基]苯甲酸酯及其制备方法 |
| JP2018517788A (ja) | 2015-06-16 | 2018-07-05 | スペクトラム・ファーマシューティカルズ，インコーポレイテッド | リンパ腫を治療するためにベリノスタットおよびプララトレキサートを使用する組合せ療法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4393064A (en) | 1976-03-05 | 1983-07-12 | Sri International | Process and composition for treatment of leukemia and process for preparing the same |
| US4652533A (en) | 1983-04-28 | 1987-03-24 | Pandex Laboratories, Inc. | Method of solid phase immunoassay incorporating a luminescent label |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| EP0487289B1 (de) | 1990-11-20 | 1996-09-04 | BEHRINGWERKE Aktiengesellschaft | Immunotest für Cyclosporin |
| US5354751A (en) | 1992-03-03 | 1994-10-11 | Sri International | Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis |
| US5981592A (en) * | 1995-03-13 | 1999-11-09 | Loma Linda University Medical Center | Method and composition for treating cystic fibrosis |
| US6323205B1 (en) | 1996-07-17 | 2001-11-27 | Sloan-Kettering Institute For Cancer Research | Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors |
| JP2001505537A (ja) * | 1996-07-17 | 2001-04-24 | スローン―ケッタリング インスティチュート フォー キャンサー リサーチ | １０―プロパルギル―１０―デアザアミノプテリンの精製組成物と腫瘍の治療への同化合物の使用方法 |
| GB0128510D0 (en) * | 2001-11-28 | 2002-01-23 | Novartis Ag | Organic compounds |
| ATE405272T1 (de) | 2004-05-30 | 2008-09-15 | Sloan Kettering Inst Cancer | Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin |
-
2005
- 2005-05-31 AT AT05756183T patent/ATE405272T1/de active
- 2005-05-31 KR KR1020117012373A patent/KR101189693B1/ko not_active Expired - Lifetime
- 2005-05-31 ES ES05756183T patent/ES2313365T3/es not_active Expired - Lifetime
- 2005-05-31 NZ NZ576849A patent/NZ576849A/en not_active IP Right Cessation
- 2005-05-31 HR HR20080569T patent/HRP20080569T3/xx unknown
- 2005-05-31 WO PCT/US2005/019169 patent/WO2005117891A1/en not_active Ceased
- 2005-05-31 PL PL05756183T patent/PL1750716T3/pl unknown
- 2005-05-31 DK DK05756183T patent/DK1750716T3/da active
- 2005-05-31 AU AU2005249516A patent/AU2005249516B2/en not_active Expired
- 2005-05-31 WO PCT/US2005/019170 patent/WO2005117892A1/en not_active Ceased
- 2005-05-31 RS RSP-2008/0470A patent/RS50622B/sr unknown
- 2005-05-31 ZA ZA200609266A patent/ZA200609266B/xx unknown
- 2005-05-31 BR BRPI0510895-0A patent/BRPI0510895A/pt not_active Application Discontinuation
- 2005-05-31 US US11/141,868 patent/US7622470B2/en not_active Expired - Lifetime
- 2005-05-31 EP EP05756183A patent/EP1750716B1/de not_active Expired - Lifetime
- 2005-05-31 CN CN201210342831.8A patent/CN102824346B/zh not_active Expired - Lifetime
- 2005-05-31 SI SI200530392T patent/SI1750716T1/sl unknown
- 2005-05-31 CA CA2565968A patent/CA2565968C/en not_active Expired - Lifetime
- 2005-05-31 MX MXPA06013559A patent/MXPA06013559A/es active IP Right Grant
- 2005-05-31 NZ NZ551082A patent/NZ551082A/en not_active IP Right Cessation
- 2005-05-31 JP JP2007515512A patent/JP5005532B2/ja not_active Expired - Lifetime
- 2005-05-31 DE DE602005009176T patent/DE602005009176D1/de not_active Expired - Lifetime
- 2005-05-31 CN CNA2005800173160A patent/CN1960734A/zh active Pending
- 2005-05-31 PT PT05756183T patent/PT1750716E/pt unknown
- 2005-05-31 US US11/568,254 patent/US7939530B2/en active Active
- 2005-05-31 ME MEP-2008-310A patent/ME01087B/me unknown
-
2006
- 2006-12-22 NO NO20065971A patent/NO337276B1/no unknown
-
2009
- 2009-10-21 US US12/603,117 patent/US8299078B2/en not_active Expired - Lifetime
-
2012
- 2012-10-29 US US13/663,234 patent/US20130053391A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE405272T1 (de) | Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin | |
| ATE302003T1 (de) | Zubereitungen enthaltend apomorphin und sildenafil und ihre verwendung zur behandlung von erektiler dysfunktion | |
| RU2007132181A (ru) | ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| CY1108217T1 (el) | Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης | |
| CY1107262T1 (el) | Θεραπεια της εξαρτησης στερησης | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| RU2013123646A (ru) | Комбинированная композиция | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| MX2009003532A (es) | Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina. | |
| RU2007101695A (ru) | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения | |
| CY1118486T1 (el) | Λαπατινιμπη για τη θεραπεια του καρκινου | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| RU2009101026A (ru) | Применение тимозина-альфа-1 для получения лекарственного средства для лечения злокачественной меланомы на iv стадии | |
| AR023185A1 (es) | Tratamiento de cancer mejorado con temozolomida | |
| WO2001080895A3 (en) | Methods and compositions for the treatment of cardiac indications | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| RU2003113210A (ru) | Лечение раковых заболеваний | |
| AR029160A1 (es) | El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo | |
| MX2010006310A (es) | O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor. | |
| DK1697401T3 (da) | Tetrapeptid, som regulerer blodglucoseniveauet ved diabetes mellitus | |
| MX2025001116A (es) | Terapia de combinacion contra el cancer que incluye un inhibidor de flt3 | |
| EA200601581A1 (ru) | Пептид, стимулирующий регенерацию ткани печени, фармацевтическая композиция на его основе и способ ее применения | |
| UA3797U (uk) | Спосіб лікування тяжких проникаючих поранень ока |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1750716 Country of ref document: EP |